Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
22nd Century Limited, LLC
22nd Century Continuing Development of its Smoking Cessation Aid; Independent Review of Clinical Trials Involving Very Low Nicotine Cigarettes is Encouraging
November 11th, 2009
22nd Century Limited, LLC ("22nd Century") is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as 'nicotine-free' and 'denicotinized,' may be more effective for quitting than FDA-approved therapies. 22nd Century's vice-president of research and development, Michael R. Moynihan, Ph.D. recently presented an overview of clinical investigations using very low nicotine (VLN) cigarettes in promoting smoking cessation in a presentation entitled, "Smoking with Reduced Reward as an Aid to Cessation" at the Visiongain 3rd Annual Smoking...
Source: Medical Patent Law Weekly (2009-11-11)
|
